Today we announced that nearly 500 payers and providers purchased or renewed InterQual®, our flagship evidence-based clinical decision support solution, and related decision management solutions in the first six months of the year. Read the release for the full story.
Today we opened the 28th annual McKesson Health Solutions Conference, where over 300 healthcare professionals from leading payers and providers come together for a week of networking, learning, and focusing on a better future for healthcare. This year MHSC takes place at the Aria Resort in Las Vegas. McKesson executives and customers will discuss key industry issues and share ideas, experiences, and best practices for simplifying and transforming reimbursement with the new healthcare consumer in mind. Next year MHSC arrives in Orlando, Fla. If you'd like to attend, set a bookmark to the MHS Conference event page, and keep an…
Today we announced that 622 payers and providers have chosen InterQual® Criteria in recent months to help support their care decisions. A wide array of health plans and hospitals, both public and private, are reflected in these 622 new agreements and renewals. New customers. A renewal rate that exceeds 96%. Broad market acceptance. This industry momentum is one of many reasons why we say InterQual is the leading choice for evidence-based clinical decision support. And there's more news to share with you about the momentum of our decision management solutions overall. Please read the full news release here.
What does healthcare want from Santa this year? Listen in as providers, payers, and patients hop on Santa's lap and tell him what they want this holiday season and beyond. A Happy Healthcare Holiday from McKesson Want a LARGER VERSION? Click here or click the "View Fullscreen" icon above.
You can't discuss healthcare reform without talking about healthcare insurance exchanges. Certainly they play a central role in the Affordable Care Act, and the focus on enrollment has become an annual industry ritual. But there's another healthcare exchange, centered around molecular diagnostics, that you might not have heard about. Drug Discovery News recently featured it in detail as a commentary by Doug Moeller, MD, Medical Director for McKesson Health Solutions. Dr. Moeller discusses how the number of molecular diagnostic tests is growing faster than payers and providers can manage, and how a cloud-based diagnostics exchange can help them uniquely identify each test, evaluate the clinical utility, accelerate new tests to market, and…
In Advance for Laboratory, McKesson medical director Douglas Moeller, MD, explains what Z-Code Identifiers are and why they're needed to identify molecular diagnostic tests. Dr. Moeller also explains how they can work alongside CPT codes to uniquely identify tests, help labs bring their tests to market, and help speed reimbursement. Read the full article here
Adult infectious disease specialist Summerpal Kahlon, MD, has some advice for physicians across America who are now fielding frantic questions from patients about Ebola. Read Dr. Kahlon's article on actions to take and actions to avoid.
On OncLive, McKesson Health Solution's Medical Director Douglas Moeller, MD, details the role of Z-code identifiers and the McKesson Diagnostics Exchange in cataloging molecular diagnostic tests. "It allows healthcare stakeholders to make decisions on genetic tests based on their clinical and financial impact, which ultimately reduces disease burden and improves health outcomes," Dr. Moeller says. The article also explains how the catalog helps speed the process for test inventors and laboratories, including: Using Z-code identifiers, a test inventor can obtain a unique identifier during the clinical evidence justification process, allowing specific communication and publication of data regarding the new technology during…
On a Reach MD podcast, Brian McDonough, MD, talks with Doug Moeller, MD, Medical Director at McKesson Health Solutions, about how physicians can be prepared to support and manage patients undergoing DNA testing. He warns that there are risks to genetic testing such as uncovering latent medical diseases and disorders or uncovering surprising family findings. With more than 14,000 registered genetic tests, being prepared to counsel patients is a challenging yet critical undertaking. Listen to his podcast here
[8-6-2014] In OncLive, McKesson Health Solutions Medical Director Douglas Moeller, MD, has advice for physicians who need to make judicious decisions about molecular testing. Look at the tests your practice uses most often and classify them into one of six categories: screening, diagnostic, predictive risk, prognostic risk, companion diagnostics and panel testing. Read the full article here.